JP2023550480A - ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用 - Google Patents

ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用 Download PDF

Info

Publication number
JP2023550480A
JP2023550480A JP2023530809A JP2023530809A JP2023550480A JP 2023550480 A JP2023550480 A JP 2023550480A JP 2023530809 A JP2023530809 A JP 2023530809A JP 2023530809 A JP2023530809 A JP 2023530809A JP 2023550480 A JP2023550480 A JP 2023550480A
Authority
JP
Japan
Prior art keywords
protein
polypeptide
polynucleotide
hpv6
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550480A5 (enExample
Inventor
ボロー，ダグラス，イー．
エティレディ，ダモダー，アール．
ヤン，チー
ワン，チェン
Original Assignee
プレシゲン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレシゲン，インコーポレイテッド filed Critical プレシゲン，インコーポレイテッド
Publication of JP2023550480A publication Critical patent/JP2023550480A/ja
Publication of JP2023550480A5 publication Critical patent/JP2023550480A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023530809A 2020-11-25 2021-11-23 ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用 Pending JP2023550480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118222P 2020-11-25 2020-11-25
US63/118,222 2020-11-25
PCT/US2021/060605 WO2022115470A1 (en) 2020-11-25 2021-11-23 Human papilloma virus vaccines and uses of the same for hpv associated diseases

Publications (2)

Publication Number Publication Date
JP2023550480A true JP2023550480A (ja) 2023-12-01
JP2023550480A5 JP2023550480A5 (enExample) 2024-12-02

Family

ID=81754898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530809A Pending JP2023550480A (ja) 2020-11-25 2021-11-23 ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用

Country Status (10)

Country Link
US (1) US20240173396A1 (enExample)
EP (1) EP4251278A4 (enExample)
JP (1) JP2023550480A (enExample)
KR (1) KR20230113331A (enExample)
CN (1) CN117203342A (enExample)
AU (1) AU2021385551A1 (enExample)
CA (1) CA3197920A1 (enExample)
IL (1) IL303113A (enExample)
MX (1) MX2023006038A (enExample)
WO (1) WO2022115470A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026518240A (ja) * 2023-05-22 2026-06-04 プレシゲン，インコーポレイテッド 再発性呼吸器乳頭腫症の処置のための新規アデノウイルスワクチン療法
KR20260032470A (ko) * 2023-05-22 2026-03-09 프레시전 인코포레이티드 Hpv 백신 요법의 결과로 생성된 t 세포 수용체 및 이를 이용하여 환자를 치료하는 방법
CN117965634B (zh) * 2024-04-01 2024-07-12 北京唯源立康生物科技股份有限公司 一种hsv-1病毒载体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510688A (ja) * 1995-07-27 1999-09-21 シーエスエル、リミテッド パピローマウイルスのポリプロテイン構築物
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
DK1421200T3 (da) * 2001-08-23 2007-04-10 Merck & Co Inc Fluoprescerende multiplex HPV PCR-assays under anvendelse af flere fluoroforer
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP2288380B1 (en) * 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
KR102373828B1 (ko) * 2011-10-12 2022-03-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510688A (ja) * 1995-07-27 1999-09-21 シーエスエル、リミテッド パピローマウイルスのポリプロテイン構築物
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물

Also Published As

Publication number Publication date
US20240173396A1 (en) 2024-05-30
CA3197920A1 (en) 2022-06-02
EP4251278A1 (en) 2023-10-04
EP4251278A4 (en) 2025-09-03
CN117203342A (zh) 2023-12-08
WO2022115470A1 (en) 2022-06-02
KR20230113331A (ko) 2023-07-28
AU2021385551A1 (en) 2023-06-22
MX2023006038A (es) 2023-07-11
IL303113A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US20260098063A1 (en) Human papillomavirus vaccines and uses of the same
JP7262403B2 (ja) 新規の細胞タグの発現
US20250223320A1 (en) Hepatitis b vaccines and uses of the same
US20240173396A1 (en) Human Papilloma Virus Vaccines and Uses of the Same for HPV Associated Diseases
RU2850195C1 (ru) Вакцины против вируса папилломы человека и их применение для лечения заболеваний, связанных с hpv
CA3092935C (en) Hepatitis b vaccines and uses of the same
US20240390475A1 (en) Human papillomavirus vaccines and uses of the same
US20240398926A1 (en) Novel adenovirus vaccine therapy for the treatment of recurrent respiratory papillomatosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241122

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250401

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602